Doctors lax in monitoring potentially addicting drugs

Mar 03, 2011

Few primary care physicians pay adequate attention to patients taking prescription opioid drugs -- despite the potential for abuse, addiction and overdose, according to a new study by researchers at Albert Einstein College of Medicine of Yeshiva University.

The study, published in the March 2 online edition of the , found lax monitoring even of patients at high risk for opioid misuse, such as those with a history of or dependence. The findings are especially concerning considering that prescription drug abuse now ranks second (after marijuana) among illicitly used drugs, with approximately 2.2 million Americans using pain relievers nonmedically for the first time in 2009, according to the National Institute on Drug Abuse (NIDA).

"Our study highlights a missed opportunity for identifying and reducing misuse of prescribed in primary care settings," said lead author Joanna Starrels, M.D., M.S. , assistant professor of medicine at Einstein. "The finding that physicians did not increase precautions for patients at highest risk for opioid misuse should be a call for a standardized approach to monitoring."

The researchers studied administrative and medical records of more than 1,600 primary care patients for an average of two years while they received regular prescription opioids for chronic, non-cancer pain. They looked at whether patients received urine drug testing, were seen regularly in the office, or received multiple early opioid refills.

Only a small minority (8 percent) of patients were found to have undergone any urine drug testing. While such testing was more common in patients at higher risk for opioid misuse, the rate of testing among those high-risk patients was still low (24 percent). Only half of patients were seen regularly in the office, and patients at higher risk of opioid misuse were not seen more frequently than patients at lower risk. Although fewer than one-quarter (23 percent) of all patients received two or more early opioid refills, patients at greater risk for opioid misuse were more likely to receive multiple early refills.

"We were disturbed to find that patients with a drug use disorder were seen less frequently in the office and were prescribed more early refills than patients without these disorders," said Dr. Starrels. "We hope that these findings will call attention to this important safety concern."

Prescription drug misuse is a major public health problem. In a 2004 NIDA report , it was estimated that 48 million people over the age of 12 have taken prescription drugs for nonmedical uses in their lifetime – which represents approximately 20 percent of the U.S. population. Opioids, central nervous system depressants and stimulants were the drugs most commonly abused.

"Most are attuned to these problems," said Dr. Starrels, "but they haven't put sufficient strategies in place to help reduce risks." She and her co-authors recommend that physicians adopt the following risk-reduction strategies: standardize a plan of care for all patients on long-term opioids, which includes urine drug testing; schedule regular face-to-face office visits to evaluate patients' response to opioids and evidence of misuse; and stick to a previously agreed-upon refill schedule.

Explore further: Protalix signs supply deal with Brazilian govt

add to favorites email to friend print save as pdf

Related Stories

Study examines use of opioids

Aug 27, 2008

Researchers from Boston University's Slone Epidemiology Center have found that in a given week, over 10 million Americans are taking opioids, and more than 4 million are taking them regularly (at least five days per week, ...

New guidelines for prescribing opioid pain drugs published

Feb 10, 2009

A prestigious panel of pain-management experts representing the American Pain Society (APS) www.ampainsoc.org and the American Academy of Pain Medicine (AAPM) has published the first comprehensive clinical practice guidel ...

Recommended for you

Protalix signs supply deal with Brazilian govt

2 hours ago

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease ...

EU fines pharma firms over generics delay (Update)

3 hours ago

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives ...

Investigational drug improves sleep disorder among the blind

Jun 17, 2013

An investigational new drug significantly improved a common and debilitating circadian rhythm sleep disorder that frequently affects people who are completely blind, a multicenter study finds. The results were presented Monday ...

US: 'Pay to delay' generic drugs can be illegal (Update)

Jun 17, 2013

The Supreme Court ruled Monday that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and ...

Medications to prevent clots not reaching some patients

Jun 14, 2013

Researchers at Johns Hopkins report that hospitalized patients do not receive more than one in 10 doses of doctor-ordered blood thinners prescribed to prevent potentially lethal or disabling blood clots, a decision they say ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

jjoensuu
not rated yet Mar 03, 2011
sheesh, why would this be surprising? After all the doctors get more money the more the patients use those drugs.

More news stories

Antioxidant shows promise in Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.

Paralysed with fear: The story of polio

Thanks to vaccination, polio has been pushed to the brink of extinction – but can we finish the job? This is one of the big questions which a Bristol academic addresses in his new book, published next week.

EUROnu project recommends building Neutrino Factory

(Phys.org) —The European Union's Seventh Framework Programme, EUROnu, has submitted its findings to a panel at CERN. Charged with choosing a project to study the nature of matter and antimatter, the project ...

'Ugly' finding: Unattractive workers suffer more

People who are considered unattractive are more likely to be belittled and bullied in the workplace, according to a first-of-its-kind study led by a Michigan State University business scholar.